{
event: "article_read",
name: `Odyssey Outcomes Education`,
author: ``,
tags: `Cardiologie | Dyslipidemie`,
publication_date: ``,
interaction_type: "content"
}
Leer meer
Leer meer
Odyssey Outcomes Education
Praluent – Effect of Alirocumab on Mortality after ACS | Sub-analysis of the Odyssey Outcome Study
.jpg/jcr:content/image%20(68).jpg)
MAT-DK-2000820-Medtalk_OO-Mortality (1)
Gerelateerde paginas
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262
